Abstract
Purpose
The presence of deleterious variants of dihydropyrimidine-dehydrogenase gene (DPYD) is associated with 5-Fluorouracil toxicity. Most of the data are based on findings in Caucasian populations. The variant Y186C (rs115232898) is found almost exclusively in African populations and is related to low DPD function. Its prevalence may vary among African subpopulations and in African Americans. There is no information in other populations. Brazil has the biggest African population outside Africa. We studied for the first time the frequency of this mutation in African Brazilians.
Methods
We amplified exon 6 of DPYD extracted from genomic DNA of 79 healthy volunteers of genetically defined African ancestry from Southeast Brazil and 36 self-reported African descendants from Northeast Brazil in order to determine the prevalence of the variant Y186C in Brazilians of African ancestry.
Results
The variant Y186C was found in heterozygosity in two samples from Southeast (2.53%) and one from Northeast (2.77%) Brazil. Overall, the prevalence of this mutation in the 115 African Brazilians was 2.6%.
Conclusions
The variant Y186C is prevalent among Brazilians of African ancestry and should be taken in account in targeted genotyping for fluoropyrimidine risk variants.
Abbreviations
- DPD:
-
Dihydropyrimidine-dehydrogenase
- DPYD :
-
The gene encoding DPD
- FP:
-
Fluoropyrimidines
- 5FU:
-
Fluorouracil
References
Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–338
Meta-Analysis Group In Cancer, Lévy E, Piedbois P, Buyse M, Pignon JP, Rougier P, Ryan L, Hansen R, Zee B, Weinerman B, Pater J, Leichman C, Macdonald J, Benedetti J, Lokich J, Fryer J, Brufman G, Isacson R, Laplanche A, Quinaux E, Thirion P (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16:3537–3541
Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, Kerb R, Blievernicht J, Fischer J, Hofmann U, Bokemeyer C, Eichelbaum M; German 5-FU Toxicity Study Group (2008) Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 26:2131–2138
van Staveren MC, Guchelaar HJ, van Kuilenburg AB, Gelderblom H, Maring JG (2013) Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharmcogenom J 13:389–395
Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, Largiadèr CR, Jennings BA, Marinaki AM, Sanderson JD, Kleibl Z, Kleiblova P, Schwab M, Zanger UM, Palles C, Tomlinson I, Gross E, van Kuilenburg AB, Punt CJ, Koopman M, Beijnen JH, Cats A, Schellens JH (2015) Clinical relevance of DPYD variants c.1679T > G, c.1236G > A/HapB3, and c.1601G > A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16:1639–1650
Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB (2013) Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res 73:1958–1968
Nie Q, Shrestha S, Tapper EE, Trogstad-Isaacson CS, Bouchonville KJ, Lee AM, Wu R, Jerde CR, Wang Z, Kubica PA, Offer SM, Diasio RB (2017) Quantitative contribution of rs75017182 to dihydropyrimidine dehydrogenase mRNA splicing and enzyme activity. Clin Pharmacol Ther 102:662–670
The International Genome Sample Resource (IGSR). Providing ongoing support for the 1000 Genomes Project data. Genome Browsers: 1000 Genomes data in Ensemble. 2018. Available at: <http://www.internationalgenome.org/1000-genomes-browsers>
Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB (2006) Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 12:5491–5495
Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB (2007) Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism. Pharmacogenet Genom 17:973–987
Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB (2008) Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism. Pharmacogenet Genom 18:25–35
Offer SM, Lee AM, Mattison LK, Fossum C, Wegner NJ, Diasio RB (2013) A DPYD variant (Y186C) in individuals of African ancestry is associated with reduced DPD enzyme activity. Clin Pharmacol Ther 94:158–166
Ezzeldin HH, Lee AM, Mattison LK, Diasio RB (2005) Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 11(24 Pt 1):8699–8705
Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB (2014) Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res 74:2545–2554
Offer SM, Diasio RB (2014) Response to “A case of 5-FU-related severe toxicity associated with the p.Y186C DPYD variant”. Clin Pharmacol Ther 95:137
Saif MW, Lee AM, Offer SM, McConnell K, Relias V, Diasio RB (2014) A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxicity potential for an individualized medicine approach. Mayo Clin Proc 89:131–136
Zaanan A, Dumont LM, Loriot MA, Taieb J, Narjoz C (2014) A case of 5-FU-related severe toxicity associated with the p.Y186C DPYD variant. Clin Pharmacol Ther 95:136
Elraiyah T, Jerde CR, Shrestha S, Wu R, Nie Q, Giama NH, Sarangi V, Roberts LR, Offer SM, Diasio RB (2017) Novel deleterious dihydropyrimidine dehydrogenase variants may contribute to 5-fluorouracil sensitivity in an East African population. Clin Pharmacol Ther 101:382–390
Bastos-Rodrigues L, Pimenta J, Pena S (2006) The genetic structure of human populations studied through short insertion–deletion polymorphisms. Ann Hum Genet 70(Pt 5):658–665
Pritchard JK, Stephens M, Donnelly P (2010) Inference of population structure using multilocus genotype data. Genetics 155:945–959
Tishkoff SA, Reed FA, Friedlaender FR, Ehret C, Ranciaro A, Froment A, Hirbo JB, Awomoyi AA, Bodo JM, Doumbo O, Ibrahim M, Juma AT, Kotze MJ, Lema G, Moore JH, Mortensen H, Nyambo TB, Omar SA, Powell K, Pretorius GS, Smith MW, Thera MA, Wambebe C, Weber JL, Williams SM (2009) The genetic structure and history of Africans and African Americans. Science 324:1035–1044
Patin E, Lopez M, Grollemund R, Verdu P, Harmant C, Quach H, Laval G, Perry GH, Barreiro LB, Froment A, Heyer E, Massougbodji A, Fortes-Lima C, Migot-Nabias F, Bellis G, Dugoujon JM, Pereira JB, Fernandes V, Pereira L, Van der Veen L, Mouguiama-Daouda P, Bustamante CD, Hombert JM, Quintana-Murci L (2017) Dispersals and genetic adaptation of Bantu-speaking populations in Africa and North America. Science 356:543–546
Cunha-Junior GF, De Marco L, Bastos-Rodrigues L, Bolina MB, Martins FL, Pianetti GA, Cesar IC, Coelho LG (2013) (13)C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients. Cancer Chemother Pharmacol 72:1273–1282
Galarza AF, Linden R, Antunes MV, Hahn RZ, Raymundo S, da Silva AC, Staggemeier R, Spilki FR, Schwartsmann G (2016) Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies. Clin Biochem 49:1221–1226
Klein HS (2002) Homo brasilis: Aspectos Genéticos, Lingüísticos. Históricos e Socioantropológicos da Formação do Povo Brasileiro, FUNPEC-RP, Ribeirão Preto, Brasil
Kehdy FS, Gouveia MH, Machado M, Magalhães WC, Horimoto AR, Horta BL, Moreira RG, Leal TP, Scliar MO, Soares-Souza GB, Rodrigues-Soares F, Araújo GS, Zamudio R, Sant Anna HP, Santos HC, Duarte NE, Fiaccone RL, Figueiredo CA, Silva TM, Costa GN, Beleza S, Berg DE, Cabrera L, Debortoli G, Duarte D, Ghirotto S, Gilman RH, Gonçalves VF, Marrero AR, Muniz YC, Weissensteiner H, Yeager M, Rodrigues LC, Barreto ML, Lima-Costa MF, Pereira AC, Rodrigues MR, Tarazona-Santos E; Brazilian EPIGEN Project Consortium (2015) Origin and dynamics of admixture in Brazilians and its effect on the pattern of deleterious mutations. Proc Natl Acad Sci USA 112:8696–8701
Lima-Costa MF, Rodrigues LC, Barreto ML, Gouveia M, Horta BL, Mambrini J, Kehdy FS, Pereira A, Rodrigues-Soares F, Victora CG, Tarazona-Santos E, Epigen-Brazil Group (2015) Genomic ancestry and ethnoracial self-classification based on 5,871 community-dwelling Brazilians (The Epigen Initiative). Sci Rep 5:9812–9818
Funding
This work was partially funded by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação de Amparo à Pesquisa de Minas Gerais (FAPEMIG), Brazil.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Cunha-Junior, G.F., Bastos-Rodrigues, L., Azevedo, P.G. et al. Prevalence of the DPYD variant (Y186C) in Brazilian individuals of African ancestry. Cancer Chemother Pharmacol 84, 1359–1363 (2019). https://doi.org/10.1007/s00280-019-03974-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-019-03974-4